EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers

Flora Tassone, Freddy Chafota, Miguel E Rentería, Randi J Hagerman, Ellery Santos, Anna Atkinson, Nicholas G Martin, Elsdon Storey, Danuta Z Loesch iD

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Flora Tassone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Medicine, University of California, Davis, California, USA. Hauptthemen laut MEDLINE: Fragile X Messenger Ribonucleoprotein 1, Fragile X Syndrome, Tremor, Ataxia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Rebecca L. Cooper Medical Research Foundation through an Al & Val Rosenstrauss Fellowship, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Fragile X‐associated Tremor/Ataxia Syndrome (FXTAS) is the most severe late‐onset condition caused by a premutation in the FMR1 gene, characterized by expanded CGG triplet repeats of 55–200. Clinical presentations of FXTAS, including gait ataxia, kinetic tremor, cognitive decline, and rare Parkinsonism, are linked to white matter degeneration, predominantly in the middle cerebellar peduncles. Underlying pathophysiological mechanisms involve the sequestration of CGG‐binding proteins due to elevated FMR1 mRNA and repeat‐associated non‐AUG (RAN)‐initiated translation. Outside of the full presentation of FXTAS, some FMR1 premutation carriers exhibit only isolated clinical changes occurring in this syndrome. This study explored the relationship of molecular predictors of disease, either with these isolated features in patients who did not meet diagnostic criteria for FXTAS or with diagnosable FXTAS.

Methods

176 male ( N = 111) and female ( N = 65) premutation carriers were separated into three groups based on neurological/cognitive examination data: asymptomatic, non‐syndromic/presenting isolated changes, and syndromic‐FXTAS. These categories were then separately correlated with CGG repeat length and FMR1 mRNA expression levels.

Results

Regression and distributions' analyses showed that the most consistent associations of both genomic markers were with neurological severity rankings, followed by a binary definition of FXTAS status. Among other minor presentations, Parkinsonism and cognitive impairment were significantly correlated with CGG size in male samples.

Discussion

This data provides evidence for a linear relationship between FMR1 CGG size and mRNA levels, as well as both syndromic and non‐syndromic forms of neurological manifestations, which represent aspects of the premutation‐linked neurodegenerative process that persist with advancing age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeTremorAtaxiaHumansMaleFemaleAgedMiddle AgedHeterozygoteGenotypeTrinucleotide Repeat ExpansionAdultAged, 80 and over

Stichwörter der Autor:innen

CGG expansionFMR1 premutation carriersFXTASmRNA predictorsneurological involvement

Substanzen

Fragile X Messenger Ribonucleoprotein 1FMR1 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Medicine, University of California, Davis, California, USA.
  • School of Medicine and MIND Institute, University of California Davis Medical Center, Davis, California, USA.
  • Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.
  • Department of Pediatrics, University of California Davis Health, Sacramento, California, USA.
  • Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, California, USA.

ORCID-Profile: Danuta Z Loesch

Förderung

  • National Health and Medical Research Council
  • Rebecca L. Cooper Medical Research Foundation through an Al & Val Rosenstrauss Fellowship
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Tassone, F., Chafota, F., Rentería, M. E., Hagerman, R. J., Santos, E., Atkinson, A., Martin, N. G., Storey, E., & Loesch, D. Z. (2026). Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70375

Vancouver

Tassone F, Chafota F, Rentería ME, Hagerman RJ, Santos E, Atkinson A, et al. Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70375

BibTeX
@article{Tassone2026,
  author = {Tassone, Flora and Chafota, Freddy and Rentería, Miguel E and Hagerman, Randi J and Santos, Ellery and Atkinson, Anna and Martin, Nicholas G and Storey, Elsdon and Loesch, Danuta Z},
  title = {Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70375}
}
Kostenlos starten →